This company listing is no longer active
SciClone Pharmaceuticals (Holdings) Balance Sheet Health
Financial Health criteria checks 6/6
SciClone Pharmaceuticals (Holdings) has a total shareholder equity of CN¥3.3B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥4.0B and CN¥735.2M respectively. SciClone Pharmaceuticals (Holdings)'s EBIT is CN¥1.4B making its interest coverage ratio -110.5. It has cash and short-term investments of CN¥2.2B.
Key information
0%
Debt to equity ratio
CN¥0
Debt
| Interest coverage ratio | -110.5x |
| Cash | CN¥2.22b |
| Equity | CN¥3.27b |
| Total liabilities | CN¥735.18m |
| Total assets | CN¥4.00b |
Recent financial health updates
No updates
Recent updates
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings
Apr 02
Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today
Dec 14Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Jun 19SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's
May 31Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Feb 17Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Dec 02We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings
Oct 04SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings
Jul 27An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued
Jun 02Financial Position Analysis
Short Term Liabilities: 6600's short term assets (CN¥3.4B) exceed its short term liabilities (CN¥698.2M).
Long Term Liabilities: 6600's short term assets (CN¥3.4B) exceed its long term liabilities (CN¥36.9M).
Debt to Equity History and Analysis
Debt Level: 6600 is debt free.
Reducing Debt: 6600 had no debt 5 years ago.
Debt Coverage: 6600 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 6600 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/09 05:56 |
| End of Day Share Price | 2024/07/03 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SciClone Pharmaceuticals (Holdings) Limited is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | B. Riley Wealth |
| Hamed Khorsand | BWS Financial Inc. |
| Hangci Zheng | China International Capital Corporation Limited |